Skip to Main Content

Roivant Sciences, the biotech company once pitched as a Berkshire Hathaway for the pharmaceutical industry, is going public, merging with a blank-check company at a $7.3 billion valuation.

In a deal disclosed Monday, Roivant will combine with a special-purpose acquisition company, or SPAC, called Montes Archimedes Acquisition Corp., founded by private equity investor Jim Momtazee. Roivant gets the $411 million Montes raised in its initial public offering last year, plus another $200 million in new financing from a group of investors that includes Fidelity, Viking Global, SoftBank, and Palantir Technologies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!